Nul secures seed round to scale alcohol reduction platform
Nul, a UK-based HealthTech startup focused on supported alcohol reduction, has raised nearly €840,000 (about $1 million) in seed funding to accelerate its UK rollout, expand its team, and prepare for international growth. The round was led by dmg ventures, the venture arm of Daily Mail and General Trust, and BYVP, alongside a group of angel investors with backgrounds spanning technology, healthcare and consumer brands.
Matus Maar, founder and CEO of Nul, said alcohol reduction remains “one of the largest and least modernised areas in healthcare,” arguing that while telehealth has reshaped categories such as weight loss and mental health, alcohol treatment has lagged despite broad demand for discreet, accessible care.
Clinical care plus medication and digital support
Founded by Maar, who is also a co-founder of Talis Capital, Nul is building a telehealth service that combines clinical care, prescription medication and behavioural support. The company says its programme is built around naltrexone, an FDA-approved medication used to treat opioid use disorder and alcohol use disorder, aimed at reducing cravings by acting on reward pathways.
Nul delivers its offering as a fully remote, subscription-based service, including virtual consultations, ongoing clinical support and structured digital pathways based on The Sinclair Method. The startup cites clinical studies reporting success rates of up to 78% for the approach. It also lists Blueco Healthcare and Thriva among its partners.
UK launch, scaling acquisition, and crowdfunding next
Rachel Muzyczka, partner at dmg ventures, said the firm views Nul as aligned with rising demand for healthier lifestyles. With the new capital, the company plans a full UK commercial launch, to grow its clinical and product teams, and to scale customer acquisition while preparing for expansion to new markets, including the US.
In parallel, Nul said it plans to open a crowdfunding campaign on Republic Europe later this week, allowing retail investors to participate. The startup reported a UK test phase beginning in summer 2025, more than 120 paying customers, and an annualised revenue run-rate of nearly €344,000 (over £300,000). It expects to raise additional capital in 2026 as it expands.
Related
